 |
|
 |
Companies |
|
|
Altana Pharmaceutical Company Intelligence Report
Publication Date August 2006
Publisher Espicom
Product Type Report
Pages 64
ISBN Number not applicable
Product Code ESP156
|
|
|
Summary
Altana AG is an international pharmaceuticals and chemicals group with approximately 13,400 employees worldwide. The Altana Group is composed of the strategic management holding company, Altana AG, and two operating divisions, Altana Pharma AG and ALTANA Chemie AG.
Altana Pharma AG, headquartered in Konstanz, Germany, is an international pharmaceutical group with more than 8,800 employees and over 30 subsidiaries in Europe, North and Latin America, Asia, South Africa and Australia. The company concentrates on innovative pharmaceutical products in therapeutics, imaging (contrast media) and OTC medication. Therapeutics, the most important business area, is based on prescription drugs for gastrointestinal and respiratory diseases.
Current Growth Drivers
Pantozol (pantoprazole) was the third proton pump inhibitor (PPI) to be developed worldwide and has been extensively licensed to companies around the globe. In 2005, pantoprazole generated over half of Altana's pharmaceutical sales.
Key Late-Stage Products
Daxas (roflumilast) is an oral, once-daily, selective phosphodiesterase IV inhibitor, in Phase III trials for the treatment of asthma and COPD. It may also have potential in several other inflammatory conditions, including atopic dermatitis and psoriasis. The company considers Daxas to have blockbuster potential.
Pharmaceutical Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 40 Company Intelligence Reports are currently available.
|
Content
- Executive Summary
- Introduction
- Current Growth Drivers
- Key Late-Stage Products
- Key Early-Stage Products
- Financial Performance 2005
- Sales and Market Position
- Income
- Expenditure
- Capital Expenditure
- Capital Expenditure By Geographic Region
- Capital Expenditure By Business Area
- R&D Expenditure
- R&D Expenditure by Business Area
- Divisional
- Sales By Business Area
- Operating Income By Business Area
- Assets By Business Area
- Geographic
- Sales By Destination
- Assets By Geographic Area
- Pharmaceutical Sales By Destination
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Discontinued Agreements
- Pfizer
- Salix Pharmaceuticals Ltd
- 22nd August 2005
- Production
- Employees
- Employees By Business Area
- Product / R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- R&D Strategy
- Key R&D Projects
- R&D Pipeline Overview
- Sales Forecasts
- Conclusions
- Product Portfolio / Research & Development
- Major Products, Therapeutic Areas and Sales
- R&D Pipeline
- Gastrointestinal - Products
- Major Launched Products
- Pantozol
- Sales
- Pantoprazole Sales By Region
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Patents
- Generic Competition/Lawsuits
- Sales Forecast
- Gastrointestinal - R&D
- BY424
- Potassium-competitive acid blocker
- Soraprazan (BY 359)
- Gastrointestinal - Summary
- Respiratory - Products
- Major Launched Products
- Alvesco
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Clinical Trial Results - Paediatric Application
- Others
- Respiratory - R&D
- Daxas
- Clinical Trial Results - COPD
- Venticute
- Respiratory - Summary
- Other - Products
- Appendix 1 - Financial Performance
- Appendix 2 - Key Agree Ments
- Abbott
- Amersham Health
- September 1994
- Bayer
- Cyclacel Group plc
- 16th March 2005
- Evotec AG
- 25th October 2001
- 25th March 2002
- 4th November 2002
- 6th October 2004
- Gpc Biotech Ag
- 8th November 2001
- May 2002
- 15th January 2003
- 12th June 2003
- 29th October 2003
- 14th January 2004
- 23rd December 2004
- Hua Wei
- 14th July 1998
- Novartis
- Pfizer
- Protherics plc
- 13th October 1997
- 31st July and 9th August 1999
- Recordati
- 2nd January 2002
- Roche
- 26th January 2001
- sanofi-aventis
- 15th October 1999
- 27th March 2001
- Solvay/Fournier Pharma Inc
- 26th September 2001
- SR Pharma plc
- 14th May 2002
- 4th December 2002
- 16th February 2005
- Tanabe
- 15th November 2002
- Teijin Limited
- 13th September 2000
- Wyeth
- June 1996
- Appendix 3 - Infrastructure
- Research and Development Facilities
- Manufacturing Facilities
- Appendix 4 - Key Pharmaceutical
- Subsidiaries / Joint Ventures
- Subsidiaries
- Joint Ventures
- Appendix 5 - Product Index
- Index Of Tables
- Principal Operating Results
- Capital Expenditure By Geographic Region
- Capital Expenditure By Business Area
- R&D Expenditure by Business Area
- Sales By Business Area
- Operating Income By Business Area
- Assets By Business Area
- Sales By Destination
- Assets By Geographic Area
- Pharmaceutical Sales By Destination
- Employees By Business Area
- Recent Product Launches
- Recent Product Approvals
- Key R&D Projects
- Major Products, Therapeutic Areas and Sales
- R&D Pipeline
- Major Launched Products
- Pantoprazole Sales By Region
- Major Launched Products
- Index Of Charts
- Sales, Costs and Operating Income
- Capital Expenditure By Geographic Region, 2005
- Capital Expenditure By Business Area
- R&D Expenditure by Business Area
- Sales By Business Area, 2005
- Sales By Destination, 2005
- Pharmaceutical Sales By Destination, 2005
- Employees By Business Area
- Sales of Pantozol (2000A-2010E)
- Pantozal Sales (2000A-2010E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
|
|
|
